AGÕæÈ˹ٷ½

STOCK TITAN

Viridian Therapeutics Inc SEC Filings

VRDN NASDAQ

Welcome to our dedicated page for Viridian Therapeutics SEC filings (Ticker: VRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Reading a biotech filing often feels like decoding a medical journal, and Viridian Therapeutics� reports are no exception. Clinical trial timelines, antibody engineering details, and cash-runway disclosures can hide across hundreds of pages. If you have ever searched, “How do I find Viridian Therapeutics� quarterly earnings report 10-Q filing?� you already know the challenge.

Stock Titan’s AI-powered summaries turn those dense sections into plain-English insights. Open a 10-K and our platform immediately flags R&D expense trends, notes on IGF-1R antibody progress, and risk factors unique to thyroid eye disease. Need real-time alerts? We post every Viridian Therapeutics 8-K material events explained within minutes of hitting EDGAR—whether it is a phase-2 data release or a new licensing deal. For governance watchers, the proxy statement executive compensation breakdown highlights how leadership incentives align with clinical milestones.

Tracking ownership shifts is just as simple. Our dashboard lists Viridian Therapeutics insider trading Form 4 transactions alongside AI context, so you see why an executive bought or sold shares. Prefer live updates? Activate “Viridian Therapeutics Form 4 insider transactions real-time� alerts before market open. Quarterly comparisons are equally clear: the latest “Viridian Therapeutics earnings report filing analysis� shows burn-rate changes at a glance, while the “Viridian Therapeutics annual report 10-K simplified� section connects cash needs to upcoming TED trial costs.

From understanding Viridian Therapeutics SEC documents with AI to locating a single line item on deferred tax assets, every filing type�10-Q, 10-K, 8-K, S-3, or DEF 14A—is indexed, summarized, and linked. Save hours, spot pivotal disclosures early, and act with confidence.

Rhea-AI Summary

Form 4 filing overview: Clover Health Investments (CLOV) reported insider activity by Jamie L. Reynoso, listed as “CEO, Medicare Advantage.� On 30 June 2025 Ms. Reynoso earned 217,523 Class A shares through the final tranche of a March 16 2023 performance-based RSU award. To satisfy withholding taxes, the company automatically sold 85,596 shares at $2.79 per share. After the automatic sale, Ms. Reynoso’s direct ownership stands at 3,328,328 Class A shares, up roughly 132 k shares versus the prior balance.

  • Nature of transaction: “Aâ€� code denotes acquisition from equity award; “Fâ€� code denotes shares withheld for taxes—neither represents an open-market trade.
  • Cost basis: RSUs were settled at no cash cost to the insider; only the tax-withholding sale carries a market price.
  • Alignment impact: The executive retains a sizable equity stake (â‰�3.3 million shares), reinforcing incentive alignment, but no new cash investment was made.

Overall, the filing reflects routine equity-compensation vesting and related tax withholding rather than a discretionary buy or sell decision. Market impact is expected to be neutral barring other catalysts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Ralliant Corp (RAL) filed a Form 4 disclosing that director Ganesh Moorthy acquired 4,434 restricted stock units (RSUs) of common stock on 06/30/2025. The RSUs were granted at no cost (price $0) and are classified under transaction code “Aâ€� (grant, award or other acquisition).

The award will vest on the earlier of (i) the first anniversary of the grant date or (ii) immediately prior to Ralliant’s 2026 annual shareholders� meeting. Following the grant, Moorthy’s total beneficial ownership stands at 4,434 shares, held directly. No derivative securities were reported, and the filing was executed by attorney-in-fact Sarah Johnson on 07/02/2025.

The transaction represents a routine annual equity grant meant to align director incentives with shareholder interests and does not, by itself, signal a change in the company’s financial outlook.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

On 2 July 2025, Enstar Group Limited (“Enstar”) filed seven Post-Effective Amendments to Form S-8 registration statements to deregister all unsold ordinary shares that had been reserved for employee and director equity plans. The affected authorisations originally covered approximately 3.16 million ordinary shares across the following programmes:

  • 1,200,000 shares â€� 2006 Equity Incentive Plan (Reg. No. 333-141793)
  • 460,949 shares â€� 1997 Omnibus Incentive Plan and 29,422 shares â€� 2001 Outside Directors Stock Option Plan (Reg. No. 333-148862)
  • 97,862 shares â€� Deferred Compensation Plan for Non-Employee Directors (Reg. No. 333-148863)
  • 200,000 shares â€� Employee Share Purchase Plan (Reg. No. 333-149551)
  • 689,654 shares â€� 2016 Equity Incentive Plan (Reg. No. 333-212131)
  • 84,370 shares â€� A&R 2016 Equity Incentive Plan (Reg. No. 333-237259)
  • 400,000 shares â€� A&R 2016 Equity Incentive Plan (Reg. No. 333-265567)

The amendments were triggered by the completion of a merger agreement dated 29 July 2024 under which Enstar survived a series of transactions and became a wholly-owned subsidiary of Elk Bidco Limited. As no further public issuances will occur, Enstar is terminating the effectiveness of the S-8 registrations in accordance with undertakings contained in each filing. The submission is administrative and contains no new financial results. The document was signed in Hamilton, Bermuda by General Counsel Audrey B. Taranto.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

On 07/01/2025, Gartner Inc. (IT) filed a Form 4 disclosing that outside director Jose M. Gutierrez converted 32 Common Stock Equivalents (CSEs) into an equal number of Gartner common shares at $0 cost. The distribution was made under the company’s Long-Term Incentive Plan (LTIP) and is coded “J,â€� indicating an ‘otherâ€� type of transaction. Immediately before the conversion, Gutierrez received a routine LTIP grant of 32 additional CSEs priced at $406.70 per unit (Code “Aâ€�), leaving him with 226 CSEs outstanding after the offsetting distribution.
Following the reported transactions, the director’s direct ownership stands at 1,663 common shares plus the remaining 226 CSEs. The 32-share increase represents an immaterial fraction of Gartner’s ~80 million diluted shares outstanding and does not affect the public float or corporate control. The filing reflects ordinary, compensation-related equity movements rather than a discretionary open-market purchase or sale, and therefore has limited signaling value for investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

On 07/01/2025, Gartner Inc. (IT) filed a Form 4 disclosing that outside director Jose M. Gutierrez converted 32 Common Stock Equivalents (CSEs) into an equal number of Gartner common shares at $0 cost. The distribution was made under the company’s Long-Term Incentive Plan (LTIP) and is coded “J,â€� indicating an ‘otherâ€� type of transaction. Immediately before the conversion, Gutierrez received a routine LTIP grant of 32 additional CSEs priced at $406.70 per unit (Code “Aâ€�), leaving him with 226 CSEs outstanding after the offsetting distribution.
Following the reported transactions, the director’s direct ownership stands at 1,663 common shares plus the remaining 226 CSEs. The 32-share increase represents an immaterial fraction of Gartner’s ~80 million diluted shares outstanding and does not affect the public float or corporate control. The filing reflects ordinary, compensation-related equity movements rather than a discretionary open-market purchase or sale, and therefore has limited signaling value for investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

SEC Form 4 filing for Ecolab Inc. (ECL) discloses two transactions by Director David W. MacLennan on 30 Jun 2025.

  • Dividend reinvestment: 126.18 common shares acquired at $0 under the company’s Non-Employee Director Stock Option and Deferred Compensation Plan, which automatically reinvests cash dividends.
  • Open-market purchase: 43.23 common shares acquired at $267.48 per share.

Following these transactions, MacLennan’s direct holdings rise to 19,653.49 shares. He also reports indirect ownership of 3,500 shares through the Kathleen F. MacLennan Revocable Trust and 709 shares held in sibling trusts, bringing total reported beneficial ownership to 23,862.49 shares.

No derivative securities were involved, and no dispositions were reported. The filing was signed on 2 Jul 2025 by an attorney-in-fact.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

JPMorgan Chase Financial Company LLC has filed a Rule 424(b)(2) pricing supplement for $7.007 million of Auto-Callable Contingent Interest Notes linked to Alphabet Inc. (GOOGL) Class A common stock, fully and unconditionally guaranteed by JPMorgan Chase & Co. The notes price on 26 June 2025, settle on or about 1 July 2025 and mature on 31 December 2026 unless called earlier.

Key structural terms

  • Denomination: $1,000 (CUSIP 48136EQ73)
  • Initial Value (GOOGL close 26 Jun 2025): $173.54
  • Interest Barrier / Trigger Value: 64 % of Initial Value ($111.0656)
  • Contingent Interest: 10.00 % p.a. (2.50 % quarterly) with a “memoryâ€� feature; payable only if the reference stock closes â‰� Interest Barrier on a Review Date.
  • Automatic Call: If GOOGL closes â‰� Initial Value on any Review Date other than the final date, investors receive $1,000 plus all due coupons and the notes terminate early.
  • Principal at Risk: If not called and Final Value < Trigger, repayment = $1,000 + ($1,000 × Stock Return). Investors lose 1 % of principal for every 1 % decline below Initial Value, exposing them to loss of >36 % and up to 100 %.
  • Review / Payment schedule: Sept 26 2025, Dec 26 2025, Mar 26 2026, Jun 26 2026, Sept 28 2026, Dec 28 2026 (final); coupons paid five days later or at maturity.

Pricing economics

  • Price to public: $1,000; Selling commissions: $15 (1.50 %); Net proceeds: $985.
  • Estimated value at pricing: $978.50 (â‰� 97.85 % of face), reflecting internal funding rate, hedging costs and dealer margin—highlighting a 2.15 % premium paid by investors.

Illustrative payouts

  • If automatically called at first Review Date with GOOGL â‰� $173.54, total return = 2.5 %.
  • If held to maturity with GOOGL â‰� Trigger and no call, maximum total coupon income = $150 (15 % over 18 months).
  • If Final Value is 54 % of Initial (below Trigger), investor receives $540 (â€�46 % total return).

Principal risks

  • Principal and coupon risk: No principal protection; coupons contingent.
  • Credit risk: Payments depend on JPMorgan Financial and JPMorgan Chase & Co.
  • Limited upside: Return capped at cumulative coupons; no participation in GOOGL appreciation.
  • Liquidity: No exchange listing; secondary price set by JPMS and may be well below issue price.
  • Valuation gap: Issue price exceeds estimated value by $21.50 per note.
  • Tax: Issuer intends to treat notes as prepaid forward contracts with ordinary-income contingent coupons; tax treatment uncertain for both U.S. and non-U.S. holders.

The filing provides extensive risk disclosures, historical GOOGL price data, hypothetical scenarios and legal opinions, enabling investors to evaluate the structured note’s risk-return profile relative to direct equity or fixed-income alternatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Viridian Therapeutics (VRDN)?

The current stock price of Viridian Therapeutics (VRDN) is $15.67 as of July 3, 2025.

What is the market cap of Viridian Therapeutics (VRDN)?

The market cap of Viridian Therapeutics (VRDN) is approximately 1.2B.

What is the primary focus of Viridian Therapeutics Inc?

Viridian Therapeutics Inc is primarily focused on developing innovative therapies for thyroid eye disease through advanced monoclonal antibody technology targeting the IGF-1R pathway.

What is Veligrotug and how is it administered?

Veligrotug is a humanized monoclonal antibody product candidate developed by Viridian Therapeutics Inc. It is designed for intravenous administration, offering a targeted approach to modifying disease progression in thyroid eye disease.

How does the company differentiate its therapeutic approach?

The company differentiates its approach by integrating advanced antibody engineering with dual administration modalities, which enhances treatment flexibility and aligns with the specific clinical needs associated with thyroid eye disease.

What role does IGF-1R play in the company’s product development?

IGF-1R is the molecular target for Viridian Therapeutics Inc's key therapeutic candidate. By focusing on this receptor, the company aims to modulate critical biological pathways involved in the inflammatory process of thyroid eye disease.

How does Viridian Therapeutics Inc position itself within the biotech industry?

By specializing in a well-defined market segment with significant unmet medical need, the company positions itself as an expert in the niche field of thyroid eye disease through precise targeting of disease-relevant pathways and rigorous clinical research.

Does the company engage in strategic collaborations?

Yes, Viridian Therapeutics Inc enhances its research capabilities through strategic collaborations and partnerships within the scientific and biotech communities, further solidifying its expertise and operational credibility.
Viridian Therapeutics Inc

NASDAQ:VRDN

VRDN Rankings

VRDN Stock Data

1.19B
80.80M
0.12%
114.02%
11.74%
Biotechnology
Services-medical Laboratories
United States
WALTHAM